Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Finished Goods: 2016-2025

Historic Finished Goods for Corcept Therapeutics (CORT) over the last 10 years, with Sep 2025 value amounting to $8.6 million.

  • Corcept Therapeutics' Finished Goods rose 6.86% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 6.86%. This contributed to the annual value of $8.2 million for FY2024, which is 6.01% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Finished Goods stood at $8.6 million, which was up 27.93% from $6.7 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Finished Goods peaked at $9.2 million during Q4 2022, and registered a low of $4.9 million during Q3 2021.
  • Moreover, its 3-year median value for Finished Goods was $8.1 million (2023), whereas its average is $8.0 million.
  • Its Finished Goods has fluctuated over the past 5 years, first dropped by 25.09% in 2021, then skyrocketed by 48.95% in 2023.
  • Corcept Therapeutics' Finished Goods (Quarterly) stood at $6.5 million in 2021, then skyrocketed by 41.60% to $9.2 million in 2022, then dropped by 15.90% to $7.7 million in 2023, then increased by 6.01% to $8.2 million in 2024, then increased by 6.86% to $8.6 million in 2025.
  • Its Finished Goods was $8.6 million in Q3 2025, compared to $6.7 million in Q2 2025 and $8.5 million in Q1 2025.